Faculty & Staff Directory
- Associate Professor
Ph.D. 1999, University of Calgary
B.S. 1994, University of Calgary
- Ongoing research projects capitalize on our metabolomics and protein chemistry expertise to develop inhibitors of the methyl erythritol phosphate pathway to serve as new antibiotics
- Investigate alcohol and diet induced changes to the fecal and serum metabolome and correlate these biomarker changes to various stages of disease
- Develop a diagnostic blood test to identify diabetic patients suitable for transplant of insulin producing cells
- Identify microbial biomarkers for the development of a rapid diagnostic for the identification of antibiotic sensitive and resistant strains of biothreat agents
With more than 20 years of research experience, my research career is centered upon the purification and characterization of biomolecules. My research group has expertise and experience in purifying and characterizing volatile organic compounds (VOCs), non-volatile metabolites, enzymes and other proteins, nucleic acids, carbohydrates, lipids, and other small molecule metabolites. My research lab is very well equipped with modern biochemistry related instrumentation, including multiple UV-Vis spectrophotometers, two GC-FIDs, a GC-NPD, and semi-preparative and preparative HPLCs. Our metabolomics platform is centered upon an Agilent 7890A Gas Chromatograph with 5975C Mass Spectrometer, an Agilent 1290 Infinity LC with a 6530 QToF (MS/MS), and an Agilent 1100 LC-MSD (with interchangeable ESI, APPI, and APCI sources). Coupled with our custom designed software algorithms and the commercially purchased Agilent Mass Profiler Professional software package, these instruments enable a comprehensive examination of biomolecules present in biological samples.
Metabolomics | Enzymology | Small Molecule Purification | Protein Purification | Antibiotics | Isoprene Biosynthesis | Volatile Organic Compounds (VOCs)
- Ball HS, et al., Characterization and Inhibition of 1-Deoxy-d-Xylulose 5-Phosphate Reductoisomerase: A Promising Drug Target in Acinetobacter baumannii and Klebsiella pneumoniae. ACS Infect Dis. 11, 2987-2998 (2021).
- Girma MB, et al., Mechanism of Action of N-Acyl and N-Alkoxy Fosmidomycin Analogs: Mono- and Bisubstrate Inhibition of IspC from Plasmodium falciparum, a Causative Agent of Malaria. ACS Omega 26, 27630-27639 (2021).
- Dailey A, et al., VOC fingerprints: metabolomic signatures of biothreat agents with and without antibiotic resistance. Sci Rep. 10(1), 11746 (2020).
- Ball HS, et al., Inhibition of the Yersinia pestis Methylerythritol Phosphate Pathway of Isoprenoid Biosynthesis by α-Phenyl-Substituted Reverse Fosmidomycin Analogues. ACS Omega 5(10) 5170-5175 (2020).
- A. Haymond et al., A high- throughput screening campaign to identify inhibitors of DXP reductoisomerase (IspC) and MEP cytidylyltransferase (IspD). Anal Biochem 542, 63-75 (2018).
- X. Wang et al., MEPicides: α,β-unsaturated fosmidomycin analogues as DXR inhibitors against malaria. J Med Chem 61, 8847–8858 (2018).
- R. D. Couch et al., Alcohol induced alterations to the human fecal VOC metabolome. PLoS One 10(3), e0119362 (2015).
- R. D. Couch et al., The approach to sample acquisition and its impact on the derived human fecal microbiome and VOC metabolome. PLoS One 8(11), e81163 (2013).